A Phase 0/I, Open Label, Single Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Myrcludex B in Healthy Volunteers
Latest Information Update: 06 Jun 2016
At a glance
- Drugs Bulevirtide (Primary) ; Bulevirtide (Primary)
- Indications Hepatitis B; Hepatitis D
- Focus Adverse reactions; First in man
- 01 Jun 2016 Results of this trial have been published in the Journal of Hepatology, according to a Hepatera media release.
- 05 May 2016 New trial record
- 27 Apr 2016 Results published in the Journal of Hepatology